Nextcure and collaborators provide data on targets in development at american society of hematology annual meeting

Beltsville, md., dec. 13, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data in oral and poster presentations at the american society of hematology (ash) annual meeting in atlanta, georgia, and on a virtual platform. the data come from preclinical research studies in collaboration with emory university evaluating the role of siglec-15 (s15) in b cell acute lymphoblastic leukemia (b-all) and the potential to target s15 in childhood leukemia, and from preclinical research studies conducted in collaboration with vanderbilt university evaluating the impact of lair-1 expression on acute myeloid leukemia (aml) blasts and the use of lair-1 monoclonal antibodies in aml therapy.
NXTC Ratings Summary
NXTC Quant Ranking